The tariff classification and country of origin of Romidepsin Injection in dosage form
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- Therefore, we find the country of origin of the Romidepsin Injection in dosage form will be India.
Ruling text
In your letter dated September 21, 2026, you requested a tariff classification and country of origin determination ruling. Romidepsin Injection, imported in 10 mg vials, is a histone deacetylase (HDAC) inhibitor. It is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy.
The applicable subheading for the Romidepsin Injection in dosage form will be 3004.90.9218, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments… consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Antineoplastic and immunosuppressive medicaments: Other.” The general rate of duty will be free. The duties cited above are current as of this ruling’s issuance.
Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA).
Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling does not address the applicability of any additional duties, taxes, fees, exactions and/or other charges, which may apply to the goods discussed herein. This includes, but is not limited to, tariffs and other duties as provided for in Subchapter III to Chapter 99, HTSUS.
Thus, for example, in addition to the classification stated above, the merchandise covered by this ruling may also need to be reported with either the Chapter 99 provision under which an additional tariff applies or one of the Chapter 99 provisions covering exceptions to such tariffs.
For further information to assist with the importation process, please refer to the frequently updated Cargo Systems Messaging Service (CSMS) messages at https://www.cbp.gov/trade/automated/cargo-systems-messaging-service and the Trade Remedies page at https://www.cbp.gov/trade/programs-administration/trade-remedies. You also requested a country of origin determination.
You stated that the active pharmaceutical ingredient (API), Romidepsin is manufactured in India and that the finished injection in dosage form is also made in India. In India, the Romidepsin will be mixed with various inactive ingredients to produce the final Romidepsin Injection in dosage form. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N365255).